Subacute Sclerosing Panencephalitis

Akgün Ölmez

doi:10.58600/eurjther.2007-13-2-1384-arch

Authors

Akgün Ölmez Gaziantep Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları ABD Özet

DOI:

https://doi.org/10.58600/eurjther.2007-13-2-1384-arch

Keywords:

Subacute Sclerosing Panencephalitis, Measles, SSPE

Abstract

Subacute Sclerosing Panencephalitis is one of the progressive, fatal slow virus infections of the central nervous system caused by a defective or mutant measles virus. Diagnosis is based on the typical clinical features and elevated measles antibody titers in the cerebrospinal fluid. Possible underlying mechanisms of SSPE which is one of the long-term complications of measles infection in measles contracted children, clinical fetaures of SSPE patients and current treatment options will be reviewed.

Metrics

Metrics Loading ...

References

Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J 2002;78:63-70.

Dawson JR Jr. Cellular inclusions in cerebral lesions of epidemic encephalitis. Am J Pathol 1933;9:7-15.

Horta-Barbosa L, Fuccillo DA, Sever JL, Zeman W. Subacute sclerosing panencephalitis; isolation of measles virus from a brain biopsy. Nature 1969;221:974.

Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005;192:1686-1893.

Miller C, Andrew N, Rush M, Munro H, Jin L, Miller E. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002. Arch Dis Child 2004;89:1145- 1148.

Saha V, John TJ, Mukundan P, et al. High incidence of subacute sclerosing panencephalitis in south India. Epidemiol Infect 1990;104:151-156. 7. Kızamık Eliminasyon Proğramı Kızamık Saha Rehberi. TC Sağlık Bakanlığı, 2004.

Yalaz K, Anlar B, Renda Y, Aysun S, Topçu M, Özdirim E. Subacute sclerosing panencephalitis in Turkey: epidemiological features. J Trop Pediatr 1988;34:301-305.

Anlar B, Köse G, Gürer Y, Altunbaşak Ş, Haspolat Ş, Okan M. Changing epidemiological features of subacute sclerosing panencephalitis. Infection 2001;29:192-195.

Anlar B. Subacute sclerosing panencephalitis. Diagnosis and drug treatment options. CNS Drugs 1997;7:11-20.

Hotta H, Nihei K, Abe Y, et al. Full-length sequence analysis of subacute sclerosing panencephalitis (SSPE) virus, a mutant of measles virus, isolated from brain tissues of a patient shortly after onset of SSPE. Microbiol Immunol 2006;50:525-534.

Kühne Simmonds M, Brown DW, Jin L. Measles viral load may reflect SSPE disease progression. Virol J 2006;3:49.

Cerebral endothelial cell infection by measles virus in subacute sclerosing panencephalitis: ultrastructural and in situ hybridization evidence. Neuropathol Appl Neurobiol 1991;17:289-297.

Rima BK, Duprex WP. Molecular mechanisms of measles virus persistence. Virus Res 2005;111:132-147.

Dyken PR. Neuroprogressive disease of post-infectious origin: a review of a resurging subacute sclerosing panencephalitis (SSPE). Ment Retard Dev Disabil Res Rev 2001;7:217-225.

Jabbour JT, Garcia JH, Lemmi H, et al. Subacute sclerosing panencephalitis. A multidisciplanry study of eight cases. JAMA 1969;207:2248-2254.

Dyken PR, Swift A, DuRant RH. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol 1982;11:359-364.

Anlar B, Yalaz K, Ustaçelebi Ş. Clinical and laboratory findings in a series of subacute sclerosing panencephalitis. Turk J Pediatr 1988;30:85-92.

Şahin D. Subakut Sklerozan Panensefalitli Hastalarda Diazepamlı ve Midazolamlı Elektorensefalografi Bulgularının Karşılaştırılması. Gaziantep Üniversitesi Tıp Fakültesi Çocuk Sağlığı Ve Hastalıkları Ana Bilim Dalı, Uzmanlık Tezi. Gaziantep, Mayıs 2007.

Norrby E, Kristensson K. Measles virus in the brain. Brain Res Bull 1997;44:213-220.

Anlar B, Saatci I, Köse G, Yalaz K. MRI findings in subacute sclerosing panencephalitis. Neurol 1996;47:1278-1283.

Alkan A, Korkmaz L, Sığırcı A, et al. Subacute sclerosing panencephalitis: Relationship between clinical satage and diffusion-weighted imaging findings. J Magn Reson Imaging 2006;23:267-272.

Aydın K, Tatlı B, Özkan M, et al. Quantification of neurometabolites in subacute sclerosing panencephalitis by 1H-MRS. Neurol 2006;67:911-913.

Jones CE, Dyken PR, Huttenlocher PR, Jabbour JT, Maxwell KW, Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients. Lancet 1982;1:1034-1037.

Fukuyama Y, Nihei K, Matsumoto S, et al. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis- a multi-institutional collaborative study-The Inosiplex-SSPE Research Committee. Brain Dev 1987;9:270-282.

Panitch HS, Gomez-Plascencia J, Norris FH, Cantell K, Smith RA, Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurol 1986;36:562-566.

Gascon GG, Yamani S, Cafege A, Flock L, al-Sedairy S, Parhar RS, et al.Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis.Brain Dev 1993;15:346-355.

Yalaz K, Anlar B, Öktem F, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurol 1992;42:488-491.

Anlar B, Aydın ÖF, Güven A, et al. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther 2004;26:1890-1894.

Hosoya M, Mori S, Tomoda A, Mori K, Sawaishi Y, Kimura H, et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2004; 48:4631-4635.

Ceyhan M. Kızamık aşısı ve ülkemizdeki durum. Çocuk Sağlığı ve Hastalıkları Dergisi 2005;48:206-208.